Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
lunes, noviembre 02
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benitec Biopharma Inc
BNTC
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$8.50
-0.24
-2.75%
Últ. Act.: Nov 2, 11:25 AM
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Benitec Biopharma Financials
Benitec Biopharma (BNTC) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Benitec Biopharma Q4 EPS $(0.26), Inline
Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.26) per share which met the analyst consensus estimate. This is a 38.1 percent increase over losses of $(0.42) per share from the same period last year.
Benzinga Newsdesk
PRO
Benitec Biopharma Q3 EPS $(0.24) Beats $(0.27) Estimate
Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.27) by 11.11 percent. This is a 36.84 percent increase over losses of $(0.38) per share from
Benzinga Newsdesk
PRO
Benitec Biopharma Q2 EPS $(0.26) Misses $(0.22) Estimate
Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.22) by 16.59 percent. This is unchanged from the same period last year.
Benzinga Newsdesk
PRO
Benitec Biopharma Q1 EPS $(0.22) Beats $(0.41) Estimate
Benzinga Newsdesk
PRO
CORRECTION: Benitec Biopharma Q4 EPS $(0.42) Misses $(0.33) Estimate
Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.33) by 25.75 percent. This is a 30 percent increase over losses of $(0.60) per share from
Benzinga Newsdesk
PRO
Benitec Biopharma Q3 EPS $(0.24) Beats $(0.35) Estimate
Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.35) by 31.43 percent. This is a 85.37 percent increase over losses of $(1.64) per share from
Benzinga Newsdesk
